<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393182</url>
  </required_header>
  <id_info>
    <org_study_id>KLASS07(CKLASS01)</org_study_id>
    <nct_id>NCT03393182</nct_id>
  </id_info>
  <brief_title>Comparing the Quality of Life Between LADG and TLDG for Gastric Cancer_KLASS07 (CKLASS01)).</brief_title>
  <official_title>A Multicenter Randomized Controlled Trial Comparing the Quality of Life Between Laparoscopy-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric cancer_KLASS 07 (CKLASS01)(Korea-China Collaborated Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Medical College of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present randomized study is designed to compare the quality of life between the patients&#xD;
      undergoing laparoscopy-assisted and totally laparoscopic distal gastrectomy for gastric&#xD;
      cancer, and therefore to evaluate the superiority of totally laparoscopic distal gastrectomy&#xD;
      to laparoscopy-assisted distal gastrectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of this trial is the early postoperative morbidity, that is defined as&#xD;
      complications that occur within 30 days after surgery.&#xD;
&#xD;
      Early postoperative morbidity is classified as follows:&#xD;
&#xD;
      (1) wound morbidity (2) surgical site morbidity: anastomosis bleeding or leakage, duodenal&#xD;
      stump leakage, postoperative bleeding, afferent loop or efferent loop obstruction, etc.; (3)&#xD;
      lung morbidity: atelectasis, pleural effusion, empyema, pneumothorax, etc.; (4) intestinal&#xD;
      obstruction morbidity (5) urinary tract morbidity (6) intra-abadominal abscess (7)&#xD;
      postoperative pancreatitis (8) pancreatic fistula (9) intestinal fistula 10) others:&#xD;
      lymphorrhea, diarrhea, etc.&#xD;
&#xD;
      The secondary end point is the questionnaire score regarding QOL. This is assessed by the&#xD;
      Korean versions of the EORTC QLQ-C30 (version 3.0) and STO22 questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">September 17, 2021</completion_date>
  <primary_completion_date type="Actual">August 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, multi-center trial that comparing surgical complications and Quality of Life between &quot;Totally laparoscopic distal gastrectomy&quot; and &quot;Laparoscopy-assisted distal gastrectomy&quot; in Korea.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative 30-day morbidity rate</measure>
    <time_frame>Postoperative 30-day</time_frame>
    <description>Check the morbidity rate&#xD;
:Wound, seroma, hematoma, wound infection, wound dehiscence, wound evisceration, Fluid collection/Abscess, Intraabdominal bleeding, Intraluminal bleeding, Postoperative ileus, Anastomosis stenosis, Anastomosis leakage, Pancreatitis or pancreatic fistula, Complication(Pulmonary, Urinary, Renal, Hepatic, Cardiac, Endocrine) etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QOL measurement : EORTC QLQ-C30/STO22</measure>
    <time_frame>screening(pre op) / Postoperative 30-day,3-month,6-month,12-month</time_frame>
    <description>EORTC QLQ-C30/STO22</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">442</enrollment>
  <condition>Quality of Life</condition>
  <condition>Gastric Cancer</condition>
  <condition>Surgery</condition>
  <condition>Surgical Complication</condition>
  <arm_group>
    <arm_group_label>TLDG arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TLDG arm(Totally laparoscopic distal gastrectomy)&#xD;
: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LADG arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LADG arm(Laparoscopy-assisted distal gastrectomy)&#xD;
: After lymphadenectomy, gastrectomy and reconstruction procedure are performed through mini-laparotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TLDG arm</intervention_name>
    <description>After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)</description>
    <arm_group_label>TLDG arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LADG arm</intervention_name>
    <description>After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)</description>
    <arm_group_label>LADG arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic proven gastric adenocarcinoma (by preoperative gastrofiberscopy)&#xD;
&#xD;
          -  Age between 20 and 80 years old&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance statu of 0 or 1&#xD;
&#xD;
          -  Clinical stage IA (T1N0M0) or IB (T1N1M0 / T2N0M0) according to the 7th edition of the&#xD;
             American Joint Committee on Cancer system10 (Clinical stage was determined based on&#xD;
             the finding of gastrofiberscopy and abdominal computed tomography)&#xD;
&#xD;
          -  Scheduled for laparoscopic distal gastrectomy with D1+ or D2 lymphadenectomy, and&#xD;
             possible for R0 surgery by this procedures (Lymphadenectomy is performed on the basis&#xD;
             of the criteria of the Japanese Gastric Cancer Treatment Guidelines 2010 (ver.3).)&#xD;
&#xD;
          -  Patients who gave a consent and signed the formal paper permitted by Institutional&#xD;
             Review Board (IRB) after hearing a full description of the study (purpose and&#xD;
             contents) prior to the participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who received stomach surgery (i.e. gastrectomy or gastrojejunostomy) in the&#xD;
             past&#xD;
&#xD;
          -  Patients with intraabdominal adhesion due to previous intraperitoneal surgery&#xD;
&#xD;
          -  Patients who recently diagnosed with gastric cancer and received either anticancer&#xD;
             treatment or radiation therapy&#xD;
&#xD;
          -  Patients who requires combined organ resection due to aggression of gastric cancer or&#xD;
             other diseases&#xD;
&#xD;
          -  Patients who received surgeries due to primary cancer of other organs, or had&#xD;
             anticancer treatment or radiation therapy in the last five years (patients whose skin&#xD;
             basal cell carcinoma and insitu cervical cancer are completely cured are exceptions).&#xD;
&#xD;
          -  Vulnerable people who can't communicate or are pregnant (or planning to be pregnant)&#xD;
&#xD;
          -  Patients who are currently participating or participated in other clinical trials in&#xD;
             the last six months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sung soo Park, MD,PhD</last_name>
    <phone>+82-2-920-6772</phone>
    <email>kugspss@korea.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hua Huang, MD,PhD</last_name>
    <email>huahuang@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sungsoo Park, MD,PhD</last_name>
      <phone>+82-2-920-6772</phone>
      <email>kugspss@korea.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Sungsoo Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

